A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Patient Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:

• Histologically or cytologically confirmed metastatic or unresectable solid tumor.
• Has failed treatment with all standard therapies for their malignancy.
• Adequate Karnofsky Performance Status.
• An expected survival of at least 3 months.
• Adequate organ and bone marrow function.
• Signed informed consent form for study participation prior to screening.

Patient Exclusion Criteria

Patients presenting with any of the following will be excluded in the study:

• Clinically significant disease as defined by the protocol.
• Surgical therapy or other therapies within period as defined by the protocol.
• Any condition that will interfere with compliance with the protocol as determined by investigator.